Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1303Sarcoma 299Gastrointestinal 27Thoracic 25Dermatologic 24Lymphoid 23Genitourinary 23Breast 18Gynecologic 15Head & Neck 12Other hematologic neoplasm 9Plasma cell 7Endocrine 7Classical hematology 6Other solid neoplasm 4NET 2Myeloid 2

Conditions

Neuroendocrine Tumors 377Carcinoid Tumor 40Gastro-enteropancreatic neuroendocrine tumor 36Pancreatic Neoplasms 27Carcinoma, Neuroendocrine 27Neoplasms 25Adenoma, Islet Cell 23Neoplasm Metastasis 17Pheochromocytoma 16Paraganglioma 16Stomach Neoplasms 15Neuroblastoma 14Gastrointestinal Neoplasms 14Carcinoma, Hepatocellular 12Thyroid Neoplasms 11Prostatic Neoplasms 11Breast Neoplasms 11Sarcoma 10Esophageal Neoplasms 10Colorectal Neoplasms 10Lung Neoplasms 9Rectal Neoplasms 8Gastrointestinal Stromal Tumors 8Cholangiocarcinoma 8Carcinoma 8Brain Neoplasms 8Anus Neoplasms 8Liver Neoplasms 7Colonic Neoplasms 7Carcinoma, Medullary 7

Interventions

olaparib 1lutetium Lu 177 dotatate 1dactolisib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × NET × Clear all
NCT06607692 2026-04-14

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

University of Cincinnati

Phase 1 Terminated
19 enrolled
CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡